EXELIXIS INC's ticker is EXEL and the CUSIP is 30161Q104. A total of 383 filers reported holding EXELIXIS INC in Q4 2022. The put-call ratio across all filers is 0.45 and the average weighting 0.3%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $333,977 | -31.1% | 15,285 | -39.8% | 0.00% | -40.0% |
| Q2 2023 | $484,954 | +15.0% | 25,377 | +16.8% | 0.01% | 0.0% |
| Q1 2023 | $421,702 | +8.0% | 21,726 | -10.8% | 0.01% | +66.7% |
| Q4 2022 | $390,510 | -99.9% | 24,346 | -50.8% | 0.00% | -25.0% |
| Q3 2022 | $388,388,000 | +75905.5% | 49,466 | +101.6% | 0.00% | -20.0% |
| Q2 2022 | $511,000 | -0.4% | 24,538 | +8.4% | 0.01% | 0.0% |
| Q1 2022 | $513,000 | +40.9% | 22,645 | +13.8% | 0.01% | +25.0% |
| Q4 2021 | $364,000 | +24.2% | 19,894 | +43.6% | 0.00% | +33.3% |
| Q3 2021 | $293,000 | +8.1% | 13,858 | -6.9% | 0.00% | 0.0% |
| Q2 2021 | $271,000 | -16.1% | 14,878 | +4.1% | 0.00% | -25.0% |
| Q1 2021 | $323,000 | -15.4% | 14,293 | -24.5% | 0.00% | 0.0% |
| Q4 2020 | $382,000 | -99.9% | 18,920 | +32.1% | 0.00% | -42.9% |
| Q3 2020 | $350,000,000 | – | 14,324 | – | 0.01% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Meditor Group Ltd | 15,001,073 | $265,294,000 | 64.62% |
| Sargent Investment Group, LLC | 465,620 | $8,234,000 | 3.70% |
| Orbimed Advisors | 3,912,900 | $69,200,000 | 1.31% |
| Bellevue Group AG | 3,858,700 | $68,241,000 | 1.27% |
| TEALWOOD ASSET MANAGEMENT INC | 137,129 | $2,425,000 | 1.04% |
| CAPITAL MANAGEMENT CORP /VA | 200,995 | $3,555,000 | 0.97% |
| Penn Capital Management Company, LLC | 517,988 | $9,161,000 | 0.96% |
| Chicago Capital, LLC | 801,560 | $14,176,000 | 0.95% |
| Portolan Capital Management | 454,444 | $8,037,000 | 0.91% |
| INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 103,534 | $1,830,000 | 0.85% |